Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 1/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3239712 | 0.86 | HSD11B1 (0.58) | HPGDGAASMN1; SMN2MAPTHSD11B1 | |
| SCHEMBL13753550 | 0.85 | HPGD (0.76) | HPGDGAAHSD11B1ALDH1A1GRM5 | |
| SCHEMBL3237604 | 0.82 | GRM5 (0.68) | HPGDGAAMEN1KMT2ACYP1A2 | |
| SCHEMBL16254982 | 0.81 | HPGD (0.84) | HPGDGAAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL22811325 | 0.81 | HPGD (0.57) | HPGDGAAKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL15126028 | 0.80 | POLB (0.61) | MEN1KMT2ACYP2C19ALDH1A1HRH3 | |
| SCHEMBL3236002 | 0.79 | GRM5 (0.58) | HPGDMEN1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL3259879 | 0.78 | MAPT (0.70) | HPGDMEN1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL18432156 | 0.78 | KCNK3 (0.71) | HPGDHRH3 | |
| SCHEMBL21696559 | 0.77 | PKM (0.64) | GAAMEN1KMT2ACYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344456-B1 | NOVEL POTASSIUM CHANNEL BLOCKER | JAPAN TOBACCO INC (JP) | 2018-07-25 | — | — | EP | claimed |
| US-8258138-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2012-09-04 | — | — | US | claimed |
| US-20100087437-A1 | Novel Potassium Channel Blockers | XENTION LIMITED (GB) | 2010-04-08 | — | — | US | claimed |
| WO-2010023445-A1 | NOVEL POTASSIUM CHANNEL BLOCKER | XENTION LIMITED (GB) | 2010-03-04 | — | — | WO | claimed |
| EP-2344456-B1 | NOVEL POTASSIUM CHANNEL BLOCKER | JAPAN TOBACCO INC (JP) | 2018-07-25 | — | — | EP | disclosed |
| US-8258138-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2012-09-04 | — | — | US | disclosed |
| US-20100087437-A1 | Novel Potassium Channel Blockers | XENTION LIMITED (GB) | 2010-04-08 | — | — | US | disclosed |
| WO-2010023445-A1 | NOVEL POTASSIUM CHANNEL BLOCKER | XENTION LIMITED (GB) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087437-A1 | Novel Potassium Channel Blockers | KCNB1, KCNJ2, KCNJ11 | HPGD 3739/4885GAA 3857/4885MEN1 824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.